LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, and Mital Patel, Executive Vice President of Financial Planning & Analysis and Chief Administrative Officer, will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025 at 04:50 p.m. Eastern Time.
There will be simultaneous and archived webcasts available at https://event.webcasts.com/starthere.jsp?ei=1734817&tp_key=e39843ed51&tp_special=8
Details for RadNet's Presentation: | |
Date: | Tuesday, September 9, 2025 |
Time: | 04:50 p.m. Eastern Time |
Location: | Sheraton New York Times Square Hotel |
About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 405 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 team members. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$74.53 |
Daily Change: | 0.52 0.70 |
Daily Volume: | 369,205 |
Market Cap: | US$5.730B |
August 07, 2025 June 04, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load